Developer docs
API playgroundTry for free, no card

Search company profiles

Cimeio Therapeutics

Full company profile

uuid0002abu

Namestring
Cimeio Therapeutics
Legal namestring
Cimeio Therapeutics, Inc.
Websiteurl
cimeio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Cimeio Therapeutics is a development-stage biotechnology company founded in April 2022 by Versant Ventures and University of Basel researchers to develop curative cell therapies for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The company operates from Basel, Switzerland (Cimeio Therapeutics AG) and Cambridge, Massachusetts (Cimeio Therapeutics, Inc.), with a headcount of 11-50 employees and no commercial products. Its stated mission is to overcome two limitations of current cell therapy and hematopoietic stem cell transplantation: the inability to selectively eliminate diseased cells without harming healthy tissue, and the lack of safe post-transplant treatment options.

The company's core technology is the Shielded-Cell & Immunotherapy Pairs™ platform, which combines epitope-shielding gene editing with paired targeted immunotherapies. Using adenine base editors (ABE8e-SpRY), Cimeio introduces single amino acid substitutions into cell surface receptors such as CD45, CD33, and CD52, preserving receptor function while preventing binding by the paired antibody, ADC, T-cell engager, or CAR-T. The lead candidate is CIM053-SG3376, a CD45-targeting antibody-drug conjugate carrying a pyrrolobenzodiazepine (PBD) dimer payload developed with ADC Therapeutics; preclinical data published in Nature (May 2024) demonstrated complete depletion of leukemic cells with preserved long-term reconstituting HSCs in AML models. The platform is also applied to CD33 (base-edited HSPCs shielded from CD33-targeted therapy) and CD52 (shielding preserving Alemtuzumab-relevant 'don't eat me' function).

Cimeio is pre-revenue and does not commercialize products directly. Its business model is built on licensing and strategic collaborations with larger pharmaceutical partners for clinical development and commercialization. The December 2024 Kyowa Kirin collaboration, worth up to US$300 million including an upfront payment, milestone payments, and two years of committed funding, exemplifies this strategy. Additional partners include Versant Ventures (Series A lead investor), the University of Basel (academic co-founding partner), ADC Therapeutics (payload technology), and Ridgeline Discovery (recombinant protein production). Customers in the traditional sense are not yet served directly; the company ultimately targets patients with hematologic malignancies and autoimmune disorders via its partners.

Short descriptiontext

Cimeio Therapeutics is a development-stage biotech developing curative cell therapies for hematologic malignancies and autoimmune disorders using its Shielded-Cell & Immunotherapy Pairs platform, which combines epitope-shielded healthy cells with paired targeted immunotherapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy, gene editing, immunotherapy, hematopoietic stem cell, epitope shielding
Industry3 codes
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Biopharmaceuticals (Hematology)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Collaboration and Licensing Revenue
TypeLicensing Royalties
Description

Pre-revenue development stage biotech company generating income through strategic collaborations with pharmaceutical partners. Received US$300 million collaboration with Kyowa Kirin including upfront payments and potential milestone payments for developing cell therapies.

regmednet.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cimeio Therapeutics develops curative cell therapies for genetic diseases, hematologic malignancies, and severe autoimmune disorders using its proprietary Shielded-Cell & Immunotherapy Pairs™ platform. The platform pairs gene-edited, shielded healthy cells (e.g., hematopoietic stem cells) with targeted immunotherapies (such as the CD45-targeting ADC CIM053-SG3376) so that the immunotherapy selectively eliminates diseased cells while leaving shielded healthy cells intact. Lead programs include CD45-ADC plus shielded HSCs for blood cancers and CD33-shielded HSPCs for acute myeloid leukemia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Selective tumor eradication with preserved hematopoiesis in preclinical AML models
+1 more record
Product overview1 text field

Cimeio Therapeutics is a biotechnology company developing cell therapies for hematologic disorders using its proprietary Shielded Cell & Immunotherapy Pairs™ platform. The platform combines cell-shielding technology (which uses gene editing to protect healthy cells from immunotherapy) with paired immunotherapies to selectively deplete diseased cells. Key programs include CD45-targeting ADC (CIM053-SG3376) for blood cancers and CD33-targeting base editing for AML. The company leverages base editing technology to install molecular shields in hematopoietic stem cells, enabling targeted therapy without harming healthy cells.

Product and service4 records
1Shielded Cell & Immunotherapy Pairs™
CategoryCell therapy platform / biopharmaceutical platform
Description

Proprietary therapeutic platform combining cell-shielding technology with paired immunotherapies to develop curative therapies for patients with hematologic disorders; the immunotherapies deplete diseased cells while cell-shielding protects healthy cells. Targeted at pharmaceutical partners and ultimately patients with blood cancers and severe autoimmune disorders.

2Cell Shielding Technology
CategoryGene editing / cell engineering technology
Description

Gene editing capability that inserts novel protein variants into HSCs or other cell types so that cells retain their function while becoming resistant to depletion by paired immunotherapies; proven effective against antibodies, T-cell engagers, ADCs, and CAR-T cells. Licensed and developed in partnership with pharma collaborators.

3CD45-Targeting ADC (CIM053-SG3376)
CategoryTherapeutic candidate (antibody-drug conjugate)
Description

Antibody-drug conjugate (ADC) targeting the pan-hematopoietic marker CD45, using a pyrrolobenzodiazepine (PBD) dimer payload (SG3376) and a non-cleavable linker; enables antigen-specific depletion of the entire hematopoietic system, including leukemic cells. When paired with shielded HSCs, enables selective cancer eradication with preserved hematopoiesis. Developed in partnership with ADC Therapeutics.

4CD33-Targeting Base Editing Technology
CategoryResearch-stage gene editing technology / therapeutic candidate
Description

Base-edited hematopoietic stem and progenitor cells (HSPCs) that are shielded from CD33-targeted therapy while preserving CD33 expression and function, using adenine base editor ABE8e for targeted A-to-G changes; supports AML-targeted cell therapy programs.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-09
Description

Strategic collaboration worth up to US$300 million to develop cell therapies for difficult-to-treat conditions. Collaboration leverages Cimeio's novel epitope shielding and immunotherapy discovery expertise. Cimeio is eligible to receive an upfront payment and two years of continued support.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founding research institution with ongoing sponsored research collaboration. Multiple Cimeio founders and researchers hold positions at the University of Basel Department of Biomedicine and Basel University Hospital.

Strategic tierMajorTypeTechnology or Integration
Description

Collaboration with ADC Therapeutics (UK) for development of CD45-targeting antibody-drug conjugate CIM053. ADC Therapeutics provided the PBD dimer payload SG3376 and expertise in ADC development for the CIM053-SG3376 therapeutic candidate.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Allogene Therapeutics is a clinical-stage leader in allogeneic CAR-T cell therapy, developing off-the-shelf cell therapies for hematologic malignancies. It represents a broader cell therapy incumbent whose platform competes for the same patients Cimeio's shielded HSC + immunotherapy approach targets.

TypeEmerging player
Description

Cellectis is a clinical-stage gene editing and cell therapy company developing allogeneic CAR-T candidates using TALEN gene editing. Its gene editing approach to cell therapy overlaps with Cimeio's gene editing-based cell shielding technology, though Cellectis focuses on effector cell engineering.

TypeBroad incumbent
Description

CRISPR Therapeutics is a clinical-stage gene editing leader developing CRISPR/Cas9-based therapies including ex vivo cell therapies for hematologic cancers (e.g., CASGEVY). It represents an established incumbent in the gene editing cell therapy space where Cimeio operates.

TypeEmerging player
Description

Precision BioSciences is a clinical-stage gene editing company using its proprietary ARCUS platform for both in vivo gene editing and ex vivo cell therapy applications. It competes in the gene editing cell therapy space with overlapping technology approaches to Cimeio's platform.

TypeBroad incumbent
Description

Editas Medicine is a clinical-stage gene editing company developing CRISPR-based therapies for hematologic diseases and other indications. It operates as a broad incumbent in the gene editing space with overlapping technology approaches to Cimeio's base editing platform.

TypeDirect peer
Description

ADC Therapeutics is a commercial-stage biotech developing antibody-drug conjugates including pyrrolobenzodiazepine-based payloads. It is both a direct technology partner with Cimeio (providing PBD payload for CIM053-SG3376) and a peer in the hematologic cancer ADC space.

TypeDirect peer
Description

Beam Therapeutics is a leader in base editing technology, the same gene editing modality Cimeio uses for its shielding approach. Beam's larger platform and capital base make it a direct competitor in the base-editing-for-cell-therapy space, with overlapping technology and applications in hematologic diseases.

TypeDirect peer
Description

Vor BioPharma is developing engineered hematopoietic stem cell transplants paired with targeted therapies, using a similar concept of shielding healthy HSCs while targeting diseased cells. Vor's platform is the most direct conceptual competitor to Cimeio's Shielded-Cell approach in hematologic malignancies.

TypeBroad incumbent
Description

Intellia Therapeutics is a leading in vivo gene editing company developing CRISPR-based therapies. It competes in the broader gene editing therapeutics market and represents an established player with capabilities that could eventually extend into cell therapy applications similar to Cimeio's.

TypeEmerging player
Description

Magenta Therapeutics is developing antibody-drug conjugates for conditioning prior to stem cell transplant, an approach conceptually aligned with Cimeio's CD45 ADC for hematopoietic depletion. Both companies target the HSCT conditioning space with novel targeted approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cimeio Therapeutics

Cell Therapy / Biopharmaceuticals (Hematology)cimeio.com

Cimeio Therapeutics is a development-stage biotech developing curative cell therapies for hematologic malignancies and autoimmune disorders using its Shielded-Cell & Immunotherapy Pairs platform, which combines epitope-shielded healthy cells with paired targeted immunotherapies.

What Cimeio Therapeutics does

Cimeio Therapeutics is a development-stage biotechnology company founded in April 2022 by Versant Ventures and University of Basel researchers to develop curative cell therapies for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The company operates from Basel, Switzerland (Cimeio Therapeutics AG) and Cambridge, Massachusetts (Cimeio Therapeutics, Inc.), with a headcount of 11-50 employees and no commercial products. Its stated mission is to overcome two limitations of current cell therapy and hematopoietic stem cell transplantation: the inability to selectively eliminate diseased cells without harming healthy tissue, and the lack of safe post-transplant treatment options.

The company's core technology is the Shielded-Cell & Immunotherapy Pairs™ platform, which combines epitope-shielding gene editing with paired targeted immunotherapies. Using adenine base editors (ABE8e-SpRY), Cimeio introduces single amino acid substitutions into cell surface receptors such as CD45, CD33, and CD52, preserving receptor function while preventing binding by the paired antibody, ADC, T-cell engager, or CAR-T. The lead candidate is CIM053-SG3376, a CD45-targeting antibody-drug conjugate carrying a pyrrolobenzodiazepine (PBD) dimer payload developed with ADC Therapeutics; preclinical data published in Nature (May 2024) demonstrated complete depletion of leukemic cells with preserved long-term reconstituting HSCs in AML models. The platform is also applied to CD33 (base-edited HSPCs shielded from CD33-targeted therapy) and CD52 (shielding preserving Alemtuzumab-relevant 'don't eat me' function).

Cimeio is pre-revenue and does not commercialize products directly. Its business model is built on licensing and strategic collaborations with larger pharmaceutical partners for clinical development and commercialization. The December 2024 Kyowa Kirin collaboration, worth up to US$300 million including an upfront payment, milestone payments, and two years of committed funding, exemplifies this strategy. Additional partners include Versant Ventures (Series A lead investor), the University of Basel (academic co-founding partner), ADC Therapeutics (payload technology), and Ridgeline Discovery (recombinant protein production). Customers in the traditional sense are not yet served directly; the company ultimately targets patients with hematologic malignancies and autoimmune disorders via its partners.

Cimeio Therapeutics firmographics

Firmographics
Name
Cimeio Therapeutics
Legal name
Cimeio Therapeutics, Inc.
Website
https://cimeio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Cimeio Therapeutics is a development-stage biotech developing curative cell therapies for hematologic malignancies and autoimmune disorders using its Shielded-Cell & Immunotherapy Pairs platform, which combines epitope-shielded healthy cells with paired targeted immunotherapies.
Ownership category
akta.pro rank

Cimeio Therapeutics industry classification

Industry
Product category
Cell Therapy / Biopharmaceuticals (Hematology)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cell therapy
  • Gene editing
  • Immunotherapy
  • Hematopoietic stem cell
  • Epitope shielding

Where Cimeio Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cimeio Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Collaboration and Licensing Revenue: Pre-revenue development stage biotech company generating income through strategic collaborations with pharmaceutical partners. Received US$300 million collaboration with Kyowa Kirin including upfront payments and potential milestone payments for developing cell therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cimeio Therapeutics product offering

Product offering

Core offering

Cimeio Therapeutics develops curative cell therapies for genetic diseases, hematologic malignancies, and severe autoimmune disorders using its proprietary Shielded-Cell & Immunotherapy Pairs™ platform. The platform pairs gene-edited, shielded healthy cells (e.g., hematopoietic stem cells) with targeted immunotherapies (such as the CD45-targeting ADC CIM053-SG3376) so that the immunotherapy selectively eliminates diseased cells while leaving shielded healthy cells intact. Lead programs include CD45-ADC plus shielded HSCs for blood cancers and CD33-shielded HSPCs for acute myeloid leukemia.

Product overview

Cimeio Therapeutics is a biotechnology company developing cell therapies for hematologic disorders using its proprietary Shielded Cell & Immunotherapy Pairs™ platform. The platform combines cell-shielding technology (which uses gene editing to protect healthy cells from immunotherapy) with paired immunotherapies to selectively deplete diseased cells. Key programs include CD45-targeting ADC (CIM053-SG3376) for blood cancers and CD33-targeting base editing for AML. The company leverages base editing technology to install molecular shields in hematopoietic stem cells, enabling targeted therapy without harming healthy cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • Shielded Cell & Immunotherapy Pairs™ Proprietary therapeutic platform combining cell-shielding technology with paired immunotherapies to develop curative therapies for patients with hematologic disorders; the immunotherapies deplete diseased cells while cell-shielding protects healthy cells. Targeted at pharmaceutical partners and ultimately patients with blood cancers and severe autoimmune disorders.
  • Cell Shielding Technology Gene editing capability that inserts novel protein variants into HSCs or other cell types so that cells retain their function while becoming resistant to depletion by paired immunotherapies; proven effective against antibodies, T-cell engagers, ADCs, and CAR-T cells. Licensed and developed in partnership with pharma collaborators.
  • CD45-Targeting ADC (CIM053-SG3376) Antibody-drug conjugate (ADC) targeting the pan-hematopoietic marker CD45, using a pyrrolobenzodiazepine (PBD) dimer payload (SG3376) and a non-cleavable linker; enables antigen-specific depletion of the entire hematopoietic system, including leukemic cells. When paired with shielded HSCs, enables selective cancer eradication with preserved hematopoiesis. Developed in partnership with ADC Therapeutics.
  • CD33-Targeting Base Editing Technology Base-edited hematopoietic stem and progenitor cells (HSPCs) that are shielded from CD33-targeted therapy while preserving CD33 expression and function, using adenine base editor ABE8e for targeted A-to-G changes; supports AML-targeted cell therapy programs.

Quantifiable outcome

  • Selective tumor eradication with preserved hematopoiesis in preclinical AML models
  • +1 more outcomes

Companies that use Cimeio Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Cimeio Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cimeio Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • Kyowa KirincoreStrategic or Co-development Partner · 9 December 2024Strategic collaboration worth up to US$300 million to develop cell therapies for difficult-to-treat conditions. Collaboration leverages Cimeio's novel epitope shielding and immunotherapy discovery expertise. Cimeio is eligible to receive an upfront payment and two years of continued support.
  • University of BaselcoreStrategic or Co-development PartnerCo-founding research institution with ongoing sponsored research collaboration. Multiple Cimeio founders and researchers hold positions at the University of Basel Department of Biomedicine and Basel University Hospital.
  • ADC TherapeuticsmajorTechnology or IntegrationCollaboration with ADC Therapeutics (UK) for development of CD45-targeting antibody-drug conjugate CIM053. ADC Therapeutics provided the PBD dimer payload SG3376 and expertise in ADC development for the CIM053-SG3376 therapeutic candidate.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Cimeio Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Allogene Therapeutics: Allogene Therapeutics is a clinical-stage leader in allogeneic CAR-T cell therapy, developing off-the-shelf cell therapies for hematologic malignancies. It represents a broader cell therapy incumbent whose platform competes for the same patients Cimeio's shielded HSC + immunotherapy approach targets.
  • CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene editing leader developing CRISPR/Cas9-based therapies including ex vivo cell therapies for hematologic cancers (e.g., CASGEVY). It represents an established incumbent in the gene editing cell therapy space where Cimeio operates.
  • Editas Medicine: Editas Medicine is a clinical-stage gene editing company developing CRISPR-based therapies for hematologic diseases and other indications. It operates as a broad incumbent in the gene editing space with overlapping technology approaches to Cimeio's base editing platform.
  • Intellia Therapeutics: Intellia Therapeutics is a leading in vivo gene editing company developing CRISPR-based therapies. It competes in the broader gene editing therapeutics market and represents an established player with capabilities that could eventually extend into cell therapy applications similar to Cimeio's.

Emerging players

  • Cellectis: Cellectis is a clinical-stage gene editing and cell therapy company developing allogeneic CAR-T candidates using TALEN gene editing. Its gene editing approach to cell therapy overlaps with Cimeio's gene editing-based cell shielding technology, though Cellectis focuses on effector cell engineering.
  • Precision BioSciences: Precision BioSciences is a clinical-stage gene editing company using its proprietary ARCUS platform for both in vivo gene editing and ex vivo cell therapy applications. It competes in the gene editing cell therapy space with overlapping technology approaches to Cimeio's platform.
  • Magenta Therapeutics: Magenta Therapeutics is developing antibody-drug conjugates for conditioning prior to stem cell transplant, an approach conceptually aligned with Cimeio's CD45 ADC for hematopoietic depletion. Both companies target the HSCT conditioning space with novel targeted approaches.

Direct peers

  • ADC Therapeutics: ADC Therapeutics is a commercial-stage biotech developing antibody-drug conjugates including pyrrolobenzodiazepine-based payloads. It is both a direct technology partner with Cimeio (providing PBD payload for CIM053-SG3376) and a peer in the hematologic cancer ADC space.
  • Beam Therapeutics: Beam Therapeutics is a leader in base editing technology, the same gene editing modality Cimeio uses for its shielding approach. Beam's larger platform and capital base make it a direct competitor in the base-editing-for-cell-therapy space, with overlapping technology and applications in hematologic diseases.
  • Vor BioPharma: Vor BioPharma is developing engineered hematopoietic stem cell transplants paired with targeted therapies, using a similar concept of shielding healthy HSCs while targeting diseased cells. Vor's platform is the most direct conceptual competitor to Cimeio's Shielded-Cell approach in hematologic malignancies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cimeio Therapeutics social profiles

Digital presence

Cimeio Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cimeio Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Cimeio Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cimeio Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cimeio Therapeutics

What does Cimeio Therapeutics do?

Cimeio Therapeutics develops curative cell therapies for genetic diseases, hematologic malignancies, and severe autoimmune disorders using its proprietary Shielded-Cell & Immunotherapy Pairs™ platform. The platform pairs gene-edited, shielded healthy cells (e.g., hematopoietic stem cells) with targeted immunotherapies (such as the CD45-targeting ADC CIM053-SG3376) so that the immunotherapy selectively eliminates diseased cells while leaving shielded healthy cells intact. Lead programs include CD45-ADC plus shielded HSCs for blood cancers and CD33-shielded HSPCs for acute myeloid leukemia.

Is Cimeio Therapeutics a public or private company?

Cimeio Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cimeio Therapeutics founded?

Cimeio Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Cimeio Therapeutics based?

Cimeio Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Cimeio Therapeutics make money?

One revenue line is on record: collaboration and Licensing Revenue.

Who are Cimeio Therapeutics's main competitors?

Broad incumbents on record are Allogene Therapeutics, CRISPR Therapeutics, Editas Medicine and Intellia Therapeutics. Emerging players are Cellectis, Precision BioSciences and Magenta Therapeutics. Direct peers are ADC Therapeutics, Beam Therapeutics and Vor BioPharma.

Does Cimeio Therapeutics have an API?

No public API is recorded for Cimeio Therapeutics.

What industry is Cimeio Therapeutics in?

Cimeio Therapeutics's product category is Cell Therapy / Biopharmaceuticals (Hematology). Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirePrime Medicine Reports Second Quarter 2023 Financial Results and Provides Business UpdatesPrime Medicine reported Q2 2023 results with a net loss of $42.4 million and R&D expenses of $34.6 million. The company entered a collaboration with Cimeio Therapeutics and expects to initiate IND-enabling studies for PM359 in 2023. It also plans to share in vivo data in the second half of 2023.GlobeNewswirePrime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic SynPrime Medicine and Cimeio Therapeutics announced a research collaboration to combine Prime Medicine's Prime Editing platform with Cimeio's Shielded Cell and Immunotherapy Pairs (SCIP) platform. The collaboration aims to improve safety and effectiveness of hematopoietic stem cell transplants for genetic diseases, AML, and MDS, and may enable in vivo editing of HSCs to avoid transplantation. Specific financial terms were not disclosed.GlobeNewswirePrime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic SynPrime Medicine and Cimeio Therapeutics announced a research collaboration to combine Prime Medicine's Prime Editing platform with Cimeio's Shielded Cell and Immunotherapy Pairs (SCIP) platform. The goal is to improve safety and effectiveness of hematopoietic stem cell transplants for genetic diseases, AML, and MDS, and potentially enable in vivo editing of HSCs to avoid transplant. Specific financial terms were not disclosed.BioSpaceCimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASHCimeio Therapeutics presented preclinical proof-of-concept data for its SCIP platform at the American Society of Hematology meeting in New Orleans. The data show that genetically engineered CD117 and CD123 shielded cells remain functional and evade targeted immunotherapy, enabling safer conditioning for hematopoietic stem cell transplantation.BioSpaceCimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy PlatformCimeio Therapeutics announced issuance of U.S. Patent 11,499,168 covering a method for in vivo selective depletion of edited or non-edited primary hematopoietic cells. The patent, developed by founder Lukas Jeker, provides broad protection for the company's SCIP platform, which uses genome editing to shield cells from immunotherapy depletion. Cimeio is advancing its first programs toward clinical development for genetic and malignant hematologic diseases.FinSMEsCimeio Therapeutics Raises $50M in Series A FundingCimeio Therapeutics, a Basel and Boston-based biotech, raised $50M in Series A funding led by Versant Ventures. The company develops Shielded-Cell & Immunotherapy Pairs for genetic diseases, hematologic malignancies, and autoimmune disorders, with first programs advancing toward clinical development in 2023.BioSpaceVersant Ventures Launches Cimeio Therapeutics with $50 Million Series AVersant Ventures launched Cimeio Therapeutics, a cell therapy company, with a $50 million Series A. Cimeio's platform uses gene editing to shield transplanted cells from immunotherapy depletion, targeting rare genetic diseases, hematologic malignancies, and autoimmune disorders. The company plans to advance its first programs toward clinical development in 2023.FierceBiotechCimeio exits stealth with $50M, but its cell therapy technology aims to stay incognitoCimeio Therapeutics exited stealth with a $50 million Series A from Versant Ventures. The company develops shielded-cell and immunotherapy pairs for rare diseases, hematologic malignancies, and autoimmune disorders. It expects a clinical candidate for its lead program by the end of this quarter.Trust & Safety PoliciesCimeio Therapeutics Wins $50M to Power Cell-Shielding TechnologyCimeio Therapeutics completed a $50 million Series A financing round led by Versant Ventures. The funding will support its cell-shielding technology for genetic diseases, hematologic malignancies, and autoimmune disorders. The company plans to bring programs to clinical development in 2023.BioSpaceCimeio Therapeutics Wins $50M to Power Cell-Shielding TechnologyCimeio Therapeutics completed a $50 million Series A financing round led by Versant Ventures to advance its cell-shielding technology for treating genetic diseases and cancer. The funding will support the development of four lead programs, with the company aiming to enter clinical development in 2023. This investment positions Cimeio to leverage its gene-editing approach to preserve cell function while enabling targeted treatments.